Barclays raises target for Danaher stock to USD 255.00

Published on 10/09/2026 at 16:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Danaher stock stood at EUR 196.83 on October 9, 2026 in trading. Q2 revenue reached USD 6.3 billion and adjusted EPS USD 1.94.

Key points in brief

Barclays raised its Danaher price target from USD 230.00 to USD 255.00 on October 7, 2026.
Danaher stock was trading at EUR 196.83 at Lang & Schwarz on October 9, 2026 at 4:04 p.m. CEST.
Second-quarter 2026 revenue reached USD 6.3 billion and adjusted earnings per share were USD 1.94.
Danaher has scheduled its third-quarter 2026 earnings call for October 21, 2026.

Aquarellgemälde des Firmensitzes in Washington DC mit Kirschblüten und Potomac-Panorama — Danaher Corp. Unternehmenszentrale Washington DC US2358511028 als stimmungsvolles Aquarellgemälde mit Kirschblüten im Frühling, Illustration mit AI erstellt.

Danaher Corp. (ISIN US2358511028) was trading at EUR 196.83 at Lang & Schwarz on October 9, 2026 at 4:04 p.m. CEST. On October 7, 2026, Barclays raised its Danaher price target from USD 230.00 to USD 255.00 while keeping an Overweight rating, according to Markets Insider.

Three dates define the story

On July 21, 2026, Danaher reported second-quarter sales of USD 6.3 billion, core revenue growth of 3.00 percent and adjusted operating profit margin of 27.10 percent, according to Yahoo Finance. Adjusted diluted earnings per share reached USD 1.94, up 8.00 percent year over year, while free cash flow was USD 1.3 billion.

On October 1, 2026, Julie Sawyer Montgomery assumed the roles of President and Chief Executive Officer and joined Danaher's Board. Former CEO Rainer Blair is scheduled to remain a senior advisor through March 31, 2027, according to Danaher.

On October 7, 2026, Danaher announced an AI-powered autonomous laboratory designed to accelerate antibody discovery by up to 8 times. The facility is expected to operate at scale in early 2027 and could increase annual reagent generation by up to 10 times, according to Yahoo Finance.

What does the AI lab add?

The laboratory connects artificial intelligence, robotics and technologies from Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies and Molecular Devices. For Danaher, the strategic value is operational: the company is trying to turn its life sciences portfolio into a connected research workflow rather than a collection of separate instruments.

Barclays raised its target while warning that valuations in the life sciences group already reflect material upside in third-quarter and 2027 estimates. That combination makes the October 21 results important because the market will compare the new AI initiative with the underlying 2026 growth profile.

Dates investors can mark

Danaher will discuss third-quarter 2026 results on October 21, 2026, beginning at 8:00 a.m. ET, according to Danaher. The company also approved a quarterly dividend of USD 0.40 per share payable on October 30, 2026, according to FinanzNachrichten.

Danaher stock enters the results window

Danaher stock was trading at EUR 196.83 at Lang & Schwarz on October 9, 2026 at 4:04 p.m. CEST. Its primary listing is on the NYSE, where the 52-week range was USD 160.93 to USD 242.80 and market capitalization was USD 154.7 billion as of October 9, 2026.

The further course of trading is shown by the continuously updated real-time quote of Danaher Corp stock.